THRX / Theseus Pharmaceuticals stock plummets after cancer drug development stopped

Theseus Pharmaceuticals experienced significant losses after discontinuing its lead program, leaving it with a market cap of half of its current asset more_horizontal

The heavy selling pressure might have exhausted for Theseus Pharmaceuticals, Inc. (THRX) as it is technically in oversold territory now. In addition t more_horizontal

The heavy selling pressure might have exhausted for Theseus Pharmaceuticals, Inc. (THRX) as it is technically in oversold territory now. In addition t more_horizontal

Theseus (THRX) announces the discontinuation of enrollment in its phase I/II study of THE-630 in patients with gastrointestinal stromal tumors due to more_horizontal

Theseus Pharmaceuticals (NASDAQ: THRX ) stock is falling hard on Friday after the company announced poor results from a Phase 1/2 clinical trial. Acco more_horizontal

Theseus Pharmaceuticals Inc. THRX, -3.74% shares plummeted after hours Thursday after the biotech drug maker discontinued enrolling patients in the st more_horizontal

The average of price targets set by Wall Street analysts indicates a potential upside of 128.8% in Theseus Pharmaceuticals, Inc. (THRX). While the eff more_horizontal

New drug approvals and pipeline progress should maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and a solid p more_horizontal